预测类风湿关节炎、银屑病关节炎或强直性脊柱炎患者治疗依从性的大型横断面研究
本研究基于ALIGN多国横断面调查中3390例风湿科患者(RA 1943例、PsA 635例、AS 812例),分析用药信念、人口学与疾病特征及药物类型与依从性的关联,构建依从性预测模型,交叉验证AUC分别为RA 0.637、PsA 0.641、AS 0.724,完全依从预测概率范围为5%至96%。
要点
- RA、PsA和AS的简单用药依从性预测模型首次可用,有助于识别不依从高风险患者。
- TNF抑制剂治疗者、年长者及治疗危害信念或担忧较低者依从性最高。
- RA和AS中白人患者依从性更高,PsA中病程<9年者依从性更高。
核心结论
- 首次为RA、PsA和AS患者提供简单的用药依从性预测模型,可能有助于识别系统性治疗不依从的高风险患者。
研究设计与样本
- 研究人群为ALIGN多国横断面自填式调查的亚组,该调查纳入7328例常规接受系统性治疗的六种免疫介导炎症性疾病成年患者。
- 本分析纳入3390例风湿科患者,包括RA 1943例、PsA 635例、AS 812例。
- 使用药物信念问卷(BMQ)和4条目Morisky用药依从性量表(MMAS-4©)定义依从性。
主要发现
- 依从性预测模型纳入治疗类型、年龄、种族(RA和AS)或病程(PsA)及用药信念(RA和PsA为BMQ-General Harm评分;AS为BMQ-Specific Concerns评分)。
- 模型交叉验证的ROC曲线下面积分别为RA 0.637、PsA 0.641、AS 0.724。
- 完全依从(MMAS-4©=4)的预测概率范围为5%至96%。
- 与其它治疗相比,TNF抑制剂治疗者依从性最高;年长者及治疗危害信念或担忧较低者依从性更高。
- RA和AS中白人患者依从性更高,PsA中病程<9年者依从性更高。
关键数值与推荐
- 完全依从定义为MMAS-4©评分为4分。
- 依从性预测模型在RA、PsA和AS中的交叉验证AUC分别为0.637、0.641和0.724。
- 完全依从的预测概率范围为5%至96%。
临床怎么用
- 可依据治疗类型、年龄、种族或病程及用药信念识别RA、PsA和AS中不依从高风险患者。
- 对治疗危害信念或担忧较高的患者,可考虑针对性干预以改善依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This analysis explored the association of treatment adherence with beliefs about medication, patient demographic and disease characteristics and medication types in rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) to develop adherence prediction models. METHODS: The population was a subset from ALIGN, a multicountry, cross-sectional, self-administered survey study in adult patients (n=7328) with six immune-mediated inflammatory diseases who were routinely receiving systemic therapy. Instruments included Beliefs about Medicines Questionnaire (BMQ) and 4-item Morisky Medication Adherence Scale (MMAS-4©), which was used to define adherence. RESULTS: A total of 3390 rheumatological patients were analysed (RA, n=1943; PsA, n=635; AS, n=812). Based on the strongest significant associations, the adherence prediction models included type of treatment, age, race (RA and AS) or disease duration (PsA) and medication beliefs (RA and PsA, BMQ-General Harm score; AS, BMQ-Specific Concerns score). The models had cross-validated areas under the receiver operating characteristic curve of 0.637 (RA), 0.641 (PsA) and 0.724 (AS). Predicted probabilities of full adherence (MMAS-4©=4) ranged from 5% to 96%. Adherence was highest for tumour necrosis factor inhibitors versus other treatments, older patients and those with low treatment harm beliefs or concerns. Adherence was higher in white patients with RA and AS and in patients with PsA with duration of disease <9 years. CONCLUSIONS: For the first time, simple medication adherence prediction models for patients with RA, PsA and AS are available, which may help identify patients at high risk of non-adherence to systemic therapies. TRIAL REGISTRATION NUMBER: ACTRN12612000977875.
引用
- Smolen JS, Gladman D, McNeil HP, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open. 2019. PMID: 30713716. doi:10.1136/rmdopen-2017-000585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。